Search - tctmd.com

Displaying 1 - 14 of 14

Sort: Relevancy | Date

Presentation TCT 2025

TCT 69: Optimal P2Y12 inhibitor strategy after acute coronary syndrome: a network meta-analysis of randomised controlled trials

Presenter: Yousif Ahmad

October 28, 2025

Presentation TCT 2025

TCT 995: Less Is More? P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy following PCI In Acute Coronary Syndrome: A Meta-Analysis of Reconstructed Time-to-Event Data

Presenter: Paulo Roberto Tartuce Filho

October 27, 2025

Presentation TCT 2025

TCT 1677: Managing Acute Coronary Syndrome in the Context of High Thrombotic Burden and P2Y12 Inhibitor Resistance

Presenter: Amitoj Singh

October 27, 2025

Presentation TCT 2025

TCT 55: A Meta-Analysis on Safety and Efficacy of P2Y12 Inhibitor Monotherapy versus Aspirin Monotherapy After 12 Months of DAPT in Patients Post Percutaneous Coronary Intervention

Presenter: Asna Aafreen

October 26, 2025

Presentation TCT 2025

TCT 52: Differential Prognostic Impact of Potent P2Y12 inhibitors in Patients with Acute Myocardial Infarction According to Bleeding Risk

Presenter: Seung Hun Lee

October 26, 2025

News Daily News

For Monotherapy, P2Y12 Inhibitor Bests Aspirin After PCI for ACS: Meta-analysis

Yael L. Maxwell

August 14, 2025

News Daily News

Fewer MACCE With P2Y12 Inhibitor vs Aspirin Monotherapy Over 5 Years

Yael L. Maxwell

June 09, 2025

News Conference News EuroPCR 2025

Short DAPT Safe in ACS With No Ischemic Penalty: 4D-ACS

L.A. McKeown

May 30, 2025

News Conference News EuroPCR 2025

Short DAPT in High-Bleeding-Risk Patients Reduces Recurrent Events: MASTER DAPT

Yael L. Maxwell

May 23, 2025

News Daily News

AHA/ACC Issue New Performance, Quality Measures for Chronic Coronary Disease

Caitlin E. Cox

May 06, 2025

News Daily News

SCAD Story Fleshed Out by Clues About Causes, Treatment Risks

Yael L. Maxwell

March 13, 2025

News Conference News CRT 2025

Need for Rethink of Discharge Medications After LAA Closure? EMERGE

L.A. McKeown

March 12, 2025

News Daily News

ACC/AHA Release New Comprehensive ACS Guidelines

Todd Neale

February 27, 2025

News Daily News

Ischemic vs Bleeding Risks: Do Antiplatelet Guidelines Need Rethinking?

Yael L. Maxwell

January 23, 2025

Advertisement

TCT 69: Optimal P2Y12 inhibitor strategy after acute coronary syndrome: a network meta-analysis of randomised controlled trials

TCT 995: Less Is More? P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy following PCI In Acute Coronary Syndrome: A Meta-Analysis of Reconstructed Time-to-Event Data

TCT 1677: Managing Acute Coronary Syndrome in the Context of High Thrombotic Burden and P2Y12 Inhibitor Resistance

TCT 55: A Meta-Analysis on Safety and Efficacy of P2Y12 Inhibitor Monotherapy versus Aspirin Monotherapy After 12 Months of DAPT in Patients Post Percutaneous Coronary Intervention

TCT 52: Differential Prognostic Impact of Potent P2Y12 inhibitors in Patients with Acute Myocardial Infarction According to Bleeding Risk

For Monotherapy, P2Y12 Inhibitor Bests Aspirin After PCI for ACS: Meta-analysis

Fewer MACCE With P2Y12 Inhibitor vs Aspirin Monotherapy Over 5 Years

Short DAPT Safe in ACS With No Ischemic Penalty: 4D-ACS

Short DAPT in High-Bleeding-Risk Patients Reduces Recurrent Events: MASTER DAPT

AHA/ACC Issue New Performance, Quality Measures for Chronic Coronary Disease

SCAD Story Fleshed Out by Clues About Causes, Treatment Risks

Need for Rethink of Discharge Medications After LAA Closure? EMERGE

ACC/AHA Release New Comprehensive ACS Guidelines

Ischemic vs Bleeding Risks: Do Antiplatelet Guidelines Need Rethinking?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content